1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner

OncologyMedicineHealth Policy
Written By Kerrington .

In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.

Kerrington .
Previous

1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate
Next

1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees